36 research outputs found
ROC curve for the ADMA levels in predicting adverse events.
<p>The area under the curve for ADMA levels in predicting adverse events was 0.767 (95% confidence interval  =  0.654–0.879). ADMA  =  asymmetric dimethylarginine; ROC curve  =  receiver-operator characteristics curve.</p
ADMA levels in AF and non-AF patients.
<p>The ADMA levels were higher in AF patients compared to non-AF patients. In addition, non-PAF patients had higher levels of ADMA than PAF patients. ADMA  =  asymmetric dimethylarginine; AF  =  atrial fibrillation; PAF  =  paroxysmal atrial fibrillation. *P value <0.05, PAF or non-PAF versus no AF. <sup>+</sup>P value <0.05, Non-PAF versus PAF.</p
Univariate Cox regression analysis for predictors of adverse events.
<p>ADMA  =  asymmetric dimethylarginine; LVEF  =  left ventricular ejection fraction.</p
Event-free survival curve for patients with different ADMA levels.
<p>Kaplan-Meier survival analysis showed that the patients with an ADMA level ≥ 0.55 µmol/L were associated with a higher event rate compared to patients with an ADMA level <0.55 µmol/L (33.3% versus 9.3%, p = 0.001). ADMA  =  asymmetric dimethylarginine.</p
A novel noninvasive surface ECG analysis using interlead QRS dispersion in arrhythmogenic right ventricular cardiomyopathy
<div><p>Background</p><p>This study investigated the feasibility of using the precordial surface ECG lead interlead QRS dispersion (IQRSD) in the identification of abnormal ventricular substrate in arrhythmogenic right ventricular cardiomyopathy (ARVC).</p><p>Methods</p><p>Seventy-one consecutive patients were enrolled and reclassified into 4 groups: definite ARVC with epicardial ablation (Group 1), ARVC with ventricular tachycardia (VT, Group 2), idiopathic right ventricular outflow tract VT without ARVC (Group 3), and controls without VT (Group 4). IQRSD was quantified by the angular difference between the reconstruction vectors obtained from the QRS-loop decomposition, based on a principal component analysis (PCA). Electroanatomic mapping and simulated ECGs were used to investigate the relationship between QRS dispersion and abnormal substrate.</p><p>Results</p><p>The percentage of the QRS loop area in the Group 1–2 was smaller than the controls (P = 0.01). The IQRSD between V1-V2 could differentiate all VTs from control (P<0.01). Group 1–2 had a greater IQRSD than the Group 3–4 (V4-V5,P = 0.001), and Group 1 had a greater IQRSD than Group 3–4 (V6-Lead I, P<0.001). Both real and simulated data had a positive correlation between the maximal IQRSD (γ = 0.62) and the extent of corresponding abnormal substrate (γ = 0.71, both P<0.001).</p><p>Conclusions</p><p>The IQRSD of the surface ECG precordial leads successfully differentiated ARVC from controls, and could be used as a noninvasive marker to identify the abnormal substrate and the status of ARVC patients who can benefit from epicardial ablation.</p></div
(A) Scatter plot and (B) ROC curves of the IQRSD between V4-V5 and between V6-I.
<p>The IQRSD between V4-V5 separated definite ARVC from RVOT VT (borderline cases), while the IQRSD between V6-1 differentiated Group 1 Group 2. Right panel: ROC curves of IQRSD between V4-V5 and between V6-I. The area under the curve further improved after a combination of the IQRSD between V4-V5 and V6-I. (IQRSD: interlead QRS dispersion; ROC: receiver-operator characteristic).</p
(A, B) 3D electroanatomic map and (C, D) corresponding reconstruction vectors of precordial ECG (lower panel) in two ARVC patients.
<p>The spatial inhomogeneity between leads V1 and V2 (C) and between leads V6 and I (D) indicate corresponding epicardial unipolar scar (green area, less than 5.5 mV) at the right ventricle site and left lateral left ventricle, respectively.</p
Revised task force criteria in different groups of patients.
<p>Revised task force criteria in different groups of patients.</p
Baseline Clinical Characteristics of 35 Patients.
<p>* Measured by ventriculogram</p><p><sup>†</sup> Data are presented as median (range).</p><p>ARVC = arrhythmogenic right ventricular cardiomyopathy; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; NS = nonsignificant; PVC = premature ventricular contraction; RVEF = right ventricular ejection fraction; RVOT = right ventricular outflow tract; VT = ventricular tachycardia.</p><p>Baseline Clinical Characteristics of 35 Patients.</p
Noncontact mapping findings of triggers.
<p>BO = breakout; EA = earliest activation; Eg = electrogram; PNV = peak negative value; Other abbreviations are the same as <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0140167#pone.0140167.t001" target="_blank">Table 1</a>.</p><p>Noncontact mapping findings of triggers.</p